Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response makes many specific dosing and safety claims, but the provided label excerpts do not supply the needed details to verify most of them (e.g., titration/maintenance range, age/weight-based pediatric tables, missed-dose instructions, and specific interaction guidance beyond a few examples). Some claims are contradicted or unsupported by the provided excerpts (e.g., renal impairment dose adjustment; injection route specificity; interchangeability implying unchanged dose amount).
Category Scores
Accurate Statements
Briviact is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Section 1 INDICATIONS AND USAGE: “BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.”
Briviact tablets, oral solution, and injection can be used interchangeably.
Section 12.3 Pharmacokinetics (form interchangeability): “BRIVIACT tablets, oral solution, and injection can be used interchangeably.”
Briviact injection should be administered intravenously at the same dosage and same frequency as tablets and oral solution.
Section 2.1/Injection: “BRIVIACT injection should be administered intravenously at the same dosage and same frequency as BRIVIACT tablets and oral solution.” and “BRIVIACT injection is for intravenous use only.”
Unsupported Statements
Briviact dosing depends on patient age, whether it is taken as tablets or oral solution, and whether treatment is being started or switched from another anti-seizure medicine.
Provided excerpts confirm Table 1 contains recommended dosage by patient 1 month+ but do not provide start vs switch guidance or the specific determinants (e.g., switching) or age dependence details beyond the general table reference.
Briviact dosing is set out in prescribing information by seizure type and patient factors.
Label excerpt provided only states dosage is included in Table 1; it does not show seizure-type stratification or the specific structure.
Briviact dose adjustments may be made for side effects.
No excerpt provided describes dose modification specifically for side effects (only discontinuation/withdrawal guidance and warnings/precautions).
Briviact dosing is titrated to an effective maintenance range.
No excerpt provided states titration to a maintenance range.
Briviact can be administered using once-daily or twice-daily regimens depending on the prescribed dose level.
No excerpt provided includes dosing frequency options (once vs twice daily) or dose-level dependent regimens.
If clinicians adjust a patient’s Briviact dose, it is usually done gradually rather than switching to the full dose at the start.
The provided label excerpts discuss gradual withdrawal to minimize seizure worsening, but do not describe gradual dose adjustments at initiation.
Pediatric Briviact dosing is weight- and age-dependent in the Briviact label.
Excerpt provided only establishes pediatric safety/effectiveness and does not provide the pediatric dosing table details indicating weight dependence.
Pediatric dosing adjustments are based on seizure control and tolerability.
No pediatric dosing adjustment criteria are shown in the provided excerpts.
Pediatric dosing instructions may differ from adult schedules and should use the specific dosing table in the label for the child’s age/weight and formulation.
No excerpt provided includes pediatric dosing table contents (age/weight/formulation-specific instructions) or its comparison to adult schedules.
Briviact prescribing information includes guidance for renal impairment that can affect how much medicine to take and how quickly the dose may be increased.
Provided excerpt states: “Dose adjustments are not required for patients with impaired renal function” and does not support renal impairment affecting dose amount or titration pace (except dialysis recommendation not supported by dose-increase guidance).
If a Briviact dose is missed, the dose should be taken when remembered unless it is close to the next scheduled dose.
No missed-dose instructions are present in the provided label excerpts.
When a Briviact dose is missed, the patient should not take extra medicine to make up for the missed dose.
No missed-dose instructions are present in the provided label excerpts.
Briviact can be adjusted when taken with certain other medicines, particularly strong enzyme inducers or inhibitors, because they can change brivaracetam exposure.
Provided excerpts include specific interactions (rifampin, carbamazepine, phenytoin, levetiracetam) but do not mention “strong enzyme inducers or inhibitors” generally.
Briviact dose adjustment should be checked with the prescriber or pharmacist when other medications are taken, including other seizure medications.
No excerpt provided gives this general counseling statement.
For Briviact, the dose amount goal is the same between formulations, but dosing instructions differ between oral solution and tablets.
The excerpt indicates interchangeability, and injection is “same dosage and same frequency,” but the claim that the dose ‘goal is the same’ and that the dosing instructions differ in a particular way is not supported by provided excerpts.
For Briviact oral solution, dosing uses a measured volume (mL) at the prescribed strength.
The excerpt provides oral solution concentration (10 mg/mL) and tablet strengths but does not explicitly state dosing uses mL measurements.
For Briviact tablets, dosing uses fixed mg strengths.
Tablet strength list is provided, but the claim that dosing ‘uses fixed mg strengths’ is trivial; however, explicit dosing instruction linking mg strengths to dosing regimen is not provided beyond the strengths listing.
The prescriber should specify the mg dose and the exact Briviact product/formulation to use.
Label excerpts provided do not include this specific instruction phrasing.
The official prescribing information provides dosing schedules including starting dose, titration, maximum dose, and adjustments by age, impairment, and formulation.
The excerpt references Table 1 for recommended dosage but does not provide the requested components (starting dose, titration, maximum dose, etc.).
Contradictions
Low
AI Statement
Briviact prescribing information includes guidance for renal impairment that can affect how much medicine to take and how quickly the dose may be increased.
Label Reference
Section 8.6 Renal Impairment: “Dose adjustments are not required for patients with impaired renal function.”
Important Omissions
Boxed warning regarding increased risk of suicidal thoughts/behavior (and related counsel/monitoring) is not addressed in the provided claims list (no claim mentions it).
Importance:
Moderate
Hypersensitivity/serious dermatologic reaction warnings and neurologic adverse effects monitoring instructions are not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing-related claims are not supported by the supplied excerpts (titration/maintenance, frequency, pediatric table specifics, missed-dose instructions). One claim conflicts with the renal impairment excerpt (dose adjustments not required).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple specific dosing and administration assertions are not supported by the provided label excerpts, and one renal impairment claim conflicts with the excerpt.
Suggested Improvement
Limit statements to what is explicitly supported by the provided excerpts (e.g., indication, injection IV route and same dosage/frequency as oral forms, interchangeability, and the specific interaction examples including rifampin/carbamazepine/phenytoin). Remove or rephrase unsupported items (maintenance titration range, once- vs twice-daily frequency by dose level, missed-dose instructions, general pediatric weight-dependence details, and renal impairment dose-increase guidance).